Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

about

Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT

P921

Q62054245-3790A637-2105-4EA7-AA0E-9A4DD77C078C

P921

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

Item

http://www.wikidata.org/entity/Q58705101

description

scientific article published on 29 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в жовтні 2018

@uk

name

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@en

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@nl

type

Item

label

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@en

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@nl

prefLabel

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@en

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@nl

P1476

Hyperthermic Intravesical Chem ...... vasive Bladder Cancer Patients

@en

P2093

Joep J de Jong

http://www.w3.org/2001/XMLSchema#string

Joost L Boormans

http://www.w3.org/2001/XMLSchema#string

Kees Hendricksen

http://www.w3.org/2001/XMLSchema#string

Marloes Rosier

http://www.w3.org/2001/XMLSchema#string

P2860

Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party

Preventing progression and improving survival with BCG maintenance.

The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review.

The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.

Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.

Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.

Treatment options for BCG failures.

Definition and management of patients with bladder cancer who fail BCG therapy.

Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients.

Developments in intravesical therapy for non-muscle-invasive bladder cancer.

P304

395-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3233/BLC-180191

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hugh Mostafid

P577

2018-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30417050

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

6218110

http://www.w3.org/2001/XMLSchema#string

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

about

P921

P921

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932